Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:LENZ NASDAQ:NBRV NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.64-10.7%$1.97$1.09▼$3.40$203.18M0.6841,703 shs589,162 shsLENZLENZ Therapeutics$5.79-5.5%$7.07$5.23▼$50.40$192.20M0.62828,654 shs784,770 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/AOKUROnKure Therapeutics$4.46-0.4%$4.18$1.91▼$5.38$180.97M0.27476,400 shs166,171 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-5.18%-8.96%+11.59%-23.75%+20.39%LENZLENZ Therapeutics+3.90%+5.87%-8.78%-34.02%-80.45%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%OKUROnKure Therapeutics+2.28%+0.45%+1.82%+4.67%+82.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.64-10.7%$1.97$1.09▼$3.40$203.18M0.6841,703 shs589,162 shsLENZLENZ Therapeutics$5.79-5.5%$7.07$5.23▼$50.40$192.20M0.62828,654 shs784,770 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/AOKUROnKure Therapeutics$4.46-0.4%$4.18$1.91▼$5.38$180.97M0.27476,400 shs166,171 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-5.18%-8.96%+11.59%-23.75%+20.39%LENZLENZ Therapeutics+3.90%+5.87%-8.78%-34.02%-80.45%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%OKUROnKure Therapeutics+2.28%+0.45%+1.82%+4.67%+82.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.63121.71% UpsideLENZLENZ Therapeutics 2.50Moderate Buy$29.80414.68% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/AOKUROnKure Therapeutics 2.00Hold$27.00505.38% UpsideCurrent Analyst Ratings BreakdownLatest NBRV, ALEC, LENZ, and OKUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/17/2026LENZLENZ Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026LENZLENZ Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $20.005/12/2026LENZLENZ Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$39.00 ➝ $12.005/12/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $38.005/11/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026OKUROnKure Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.004/24/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M8.62N/AN/A$0.28 per share5.84LENZLENZ Therapeutics$20.99M8.65N/AN/A$9.09 per share0.64NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00OKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)LENZLENZ Therapeutics-$82.13M-$3.60N/AN/AN/A-519.30%-46.82%-43.32%7/29/2026 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/AOKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%8/11/2026 (Estimated)Latest NBRV, ALEC, LENZ, and OKUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026ALECAlector-$0.24N/AN/AN/A$1.43 millionN/A7/29/2026Q2 2026LENZLENZ Therapeutics-$1.0691N/AN/AN/A$2.49 millionN/A5/11/2026Q1 2026LENZLENZ Therapeutics-$1.10-$1.32-$0.22-$1.32$1.76 million$1.90 million5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25LENZLENZ TherapeuticsN/A10.4010.26NBRVNabriva Therapeutics0.120.850.52OKUROnKure TherapeuticsN/A13.7813.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%LENZLENZ Therapeutics54.32%NBRVNabriva Therapeutics0.27%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%LENZLENZ Therapeutics8.30%NBRVNabriva Therapeutics1.63%OKUROnKure Therapeutics2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableLENZLENZ Therapeutics11031.35 million28.75 millionN/ANBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableOKUROnKure TherapeuticsN/A40.40 million39.47 millionN/ANBRV, ALEC, LENZ, and OKUR HeadlinesRecent News About These CompaniesOnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026July 2, 2026 | globenewswire.comOnKure Therapeutics (NASDAQ:OKUR) Trading Up 1.3% - Still a Buy?July 1, 2026 | americanbankingnews.comOnKure Therapeutics, Inc. Class AJune 9, 2026 | edition.cnn.comOnKure Shareholders Approve Amended 2024 Equity Incentive PlanJune 4, 2026 | tipranks.comOnkure Therapeutics (OKUR) Stock Forecast & Price TargetMay 22, 2026 | investing.comOnKure Therapeutics (OKUR) Receives a Buy from OppenheimerMay 8, 2026 | theglobeandmail.comOnKure Therapeutics war chest nears $200M following spring stock saleMay 6, 2026 | bizwest.comBOnKure Therapeutics Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comOnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60April 28, 2026 | msn.comOnKure Therapeutics (OKUR) Gets a Buy from JonesTradingApril 26, 2026 | theglobeandmail.comOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...March 27, 2026 | finance.yahoo.comOnKure to sell $150M in stock to fund drug developmentMarch 27, 2026 | bizwest.comBOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular AnomaliesMarch 27, 2026 | globenewswire.comOnKure reports nearly $60M cash on hand as drug trials continueMarch 19, 2026 | bizwest.comBOnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX)January 24, 2026 | theglobeandmail.comOnKure Therapeutics (OKUR) Price Target Decreased by 10.00% to 27.54November 18, 2025 | msn.comOnKure Therapeutics Announces Sales Agreement with LeerinkNovember 13, 2025 | theglobeandmail.comOnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)November 7, 2025 | msn.comOnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business UpdateNovember 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBRV, ALEC, LENZ, and OKUR Company DescriptionsAlector NASDAQ:ALEC$1.64 -0.20 (-10.66%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.00 (+0.31%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.LENZ Therapeutics NASDAQ:LENZ$5.79 -0.34 (-5.55%) Closing price 04:00 PM EasternExtended Trading$5.90 +0.11 (+1.92%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.OnKure Therapeutics NASDAQ:OKUR$4.46 -0.02 (-0.45%) Closing price 04:00 PM EasternExtended Trading$4.46 0.00 (-0.09%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Dollar Tree’s Turnaround Is Starting to Take Root Constellation Brands: Beer Growth and Buybacks Mask Stock's Slump Grounded: SpaceX Stumbles as Grok Fails to Ignite Southwest MAX Incident Revives Headline Risk for Boeing and Airline Stocks Fiserv’s Debit Network Talks Raise a Bigger Question for Visa and Mastercard Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
